Tabaflex Antimicrobial Foam Dressing: An Iranian Innovation in Wound Healing and Healthcare Cost Reduction

41444

Printable

Tabaflex Antimicrobial Foam Dressing: An Iranian Innovation in Wound Healing and Healthcare Cost Reduction

The advanced Tabaflex antimicrobial foam dressing, a knowledge-based product developed using modern wound-care technologies, has been introduced into Iran’s healthcare system and successfully addressed the critical needs of patients with chronic wounds and specific dermatological conditions. Beyond improving the quality of wound care, the product has significantly reduced foreign currency outflows and dependence on imported medical dressings.

November 29, 2025 Industrial

At a time when the healthcare system faces persistent challenges in treating chronic wounds, diabetic ulcers, and rare genetic skin disorders such as epidermolysis bullosa (EB), the development of an advanced foam dressing represents a major therapeutic breakthrough. Tabaflex, produced by Trita Company, is an Iranian-made foam dressing based on micellar technology and enhanced with PHMB antimicrobial compounds, delivering performance comparable to global standards while responding directly to patient needs.

The dressing holds a manufacturing license from the Ministry of Health and has obtained international certifications, including ISO 13485, GMP, and FDA-QSR. Designed to improve wound-care quality, reduce treatment burden, and create a stable healing environment, domestic production of Tabaflex has so far resulted in USD 15.2 million in foreign currency savings, effectively replacing costly imports of similar products.

Addressing Critical Challenges in the Healthcare System

Treatment of chronic wounds has long been one of the most complex and costly areas of healthcare. High treatment expenses, limited effectiveness of conventional dressings, and shortages of specialised products have complicated care for many patients. These challenges are particularly serious for EB patients and individuals with long-term wounds, where even minor errors in dressing selection can lead to severe pain, infection, or delayed healing.

Tabaflex was developed to fill this critical gap. Its multilayer foam structure, long-lasting antimicrobial properties, and controlled moisture regulation deliver strong performance in treating chronic wounds, diabetic ulcers, pressure sores, and patients with highly sensitive skin.

Global Standards in a Locally Developed Product

Tabaflex’s innovation goes beyond its foam structure. The dressing integrates intelligent moisture management technology, formulation tailored to local patient skin profiles, and strict adherence to international wound-care standards. The use of micellar technology and PHMB antimicrobial coating enables effective microbial load control, preventing infection progression — a vital factor in chronic wound management.

Key Functional Advantages

Tabaflex offers a comprehensive set of clinical benefits, including:

Compliance with international wound-care standards
Suitability for both acute and chronic wounds, including EB patients
Effective reduction of microbial load and infection risk
Creation of a controlled moist environment to accelerate healing
Regulated adhesion throughout the treatment period
Prevention of unwanted dressing adherence to the wound bed
Reduced pain during dressing removal
High skin compatibility, even for sensitive areas
Strong fluid absorption for effective exudate management

Together, these features not only protect the wound area from secondary damage but also significantly reduce pain and stress during dressing changes — a crucial advantage for EB patients.

Economic Impact and Improved Patient Access

The domestic price of Tabaflex is approximately 220,000 IRR (around USD 2), while comparable foreign products are priced at about USD 10. This substantial price difference, combined with mass-production capability and certified quality, makes Tabaflex both cost-effective and clinically reliable.

Reduced reliance on imports, strengthening of the domestic supply chain, and expanded patient access to evidence-based wound-care solutions stand among the most important achievements of this innovation.

A Step Forward for Iran’s Medical Device Industry

The production of the Tabaflex foam dressing represents more than a new therapeutic option for clinicians and patients; it symbolises meaningful progress in Iran’s medical device industry. By achieving USD 15.2 million in foreign currency savings, enhancing wound-care quality, improving healing outcomes, and competing effectively with international products, Tabaflex has established a new position in chronic wound management and helped align the country’s medical equipment sector with global standards.